The connection between PFAS exposure and bone health is an emerging area of research that has significant implications for public health, particularly for aging populations and others at elevated osteoporosis risk. While the evidence is still accumulating, multiple studies have found associations between PFAS blood levels and bone density, fracture risk, and markers of bone metabolism.
Why PFAS May Affect Bone
Several biological mechanisms have been proposed to explain how PFAS might affect skeletal health:
Thyroid hormone disruption: PFAS are well-established thyroid disruptors. Thyroid hormones play a crucial role in bone metabolism — both hypothyroidism and hyperthyroidism are associated with bone loss and increased fracture risk. By altering thyroid function, PFAS may indirectly affect bone remodeling.
Sex hormone effects: Estrogen and testosterone are critical regulators of bone density. PFAS have been shown to interfere with sex hormone production and signaling. Lower estrogen levels, in particular, are strongly associated with osteoporosis in postmenopausal women.
Vitamin D metabolism: Some PFAS compounds appear to interfere with vitamin D metabolism. Vitamin D is essential for calcium absorption and bone mineralization. Disrupted vitamin D pathways could impair the body’s ability to maintain adequate bone density.
Direct effects on osteoblasts and osteoclasts: In vitro studies have shown that PFAS can directly affect the cells responsible for bone formation (osteoblasts) and bone resorption (osteoclasts), potentially shifting the balance toward net bone loss.
Key Epidemiological Studies
Several human studies have examined the PFAS-bone health relationship:
A 2016 study in Environmental Health Perspectives using data from the National Health and Nutrition Examination Survey (NHANES) found that higher serum PFAS levels were associated with lower bone mineral density in women aged 20–49, with the effect most pronounced at the spine. Women in the highest PFAS exposure quartile had significantly lower bone density than those in the lowest quartile.
Research using data from the C8 Health Project — the large epidemiological study of communities near the DuPont Washington Works PFOA facility in West Virginia — found associations between long-term PFOA exposure and altered bone metabolism markers, though the relationship with clinical outcomes like fractures required longer follow-up periods.
A Danish birth cohort study found that children with higher prenatal PFAS exposure had lower bone mineral content at age 20, suggesting that early-life exposure may establish a trajectory of reduced bone accumulation that affects peak bone mass — a critical determinant of lifelong fracture risk.
Menopause and PFAS: A Compounding Risk
Postmenopausal women face a particularly significant concern at the intersection of PFAS exposure and bone health. Menopause-related estrogen decline already creates substantial bone loss risk. If PFAS further suppress estrogen production or signaling, the combined effect may accelerate bone density loss beyond what would be expected from hormonal changes alone.
Studies have found associations between higher PFAS serum levels and earlier menopause onset — which would extend the period of estrogen deficiency and compound skeletal impacts.
Implications for Water Filtration
For individuals at elevated osteoporosis risk — postmenopausal women, older men, those with family history of fractures, or those with low bone density on DEXA scan — the bone health implications of PFAS exposure provide an additional compelling reason to reduce water-based PFAS intake.
Reverse osmosis systems, certified to NSF/ANSI 58, remain the most effective consumer technology for reducing drinking water PFAS exposure, achieving 90–99% removal of most PFAS compounds. For those already managing osteoporosis risk factors, adding PFAS reduction to their protective measures is a reasonable precaution.
What Remains Unknown
The field still lacks definitive evidence that reducing PFAS exposure through water filtration will measurably improve bone density or reduce fracture risk. Clinical intervention trials would be needed to establish this directly, and such trials are logistically challenging. However, the mechanistic plausibility and epidemiological associations provide a reasonable basis for precautionary action, particularly given the long half-lives of PFAS in the body and the decade-scale timelines over which bone loss accumulates.